FDA's Latest Approved Drugs and Indications Include Two Oral Agents.
- Published in:
- ONS Voice, 2019, v. 34, n. 6, p. 30
- By:
- Publication type:
- Article
Works matching IS 24756938 AND DT 2019 AND VI 34 AND IP 6
Results: 10
1
2
Oncology Drug Reference Sheet: Combination Trastuzumab and Hyaluronidase-Oysk.
- Published in:
- ONS Voice, 2019, v. 34, n. 6, p. 28
- By:
- Publication type:
- Article
3
Manage Immunotherapy-Related Diarrhea and Colitis.
- Published in:
- ONS Voice, 2019, v. 34, n. 6, p. 26
- By:
- Publication type:
- Article
4
CMS Seeks Changes in Telehealth, Palliative Care Payments, and Electronic Health Record Interoperability.
- Published in:
- ONS Voice, 2019, v. 34, n. 6, p. 18
- By:
- Publication type:
- Article
5
Survivorship Considerations After CAR T-Cell Therapy.
- Published in:
- ONS Voice, 2019, v. 34, n. 6, p. 16
- By:
- Publication type:
- Article
6
How Music Can Soothe Your Savage Beast-Stress.
- Published in:
- ONS Voice, 2019, v. 34, n. 6, p. 15
- By:
- Publication type:
- Article
7
Nurses Are Crucial to Developing Tools, Best Practices for Novel Therapies.
- Published in:
- ONS Voice, 2019, v. 34, n. 6, p. 13
- By:
- Publication type:
- Article
8
Novel Therapies: How CAR T Cells and Biosimilars Are Changing Cancer Care.
- Published in:
- ONS Voice, 2019, v. 34, n. 6, p. 8
- By:
- Publication type:
- Article
9
6 or 9? Why Persuasive Public Speaking Is Essential.
- Published in:
- ONS Voice, 2019, v. 34, n. 6, p. 5
- By:
- Publication type:
- Article
10
Think Tank Will Explore Nurse Leadership Development Initiatives.
- Published in:
- 2019
- By:
- Publication type:
- Proceeding